

IFW

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on June 2, 2004

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney

INFORMATION DISCLOSURE
STATEMENT

Examining Group 1653
Patent Application
Docket No. GJE-70D1
Serial No. 10/799,072

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)
Art Unit : 1653
Applicants : Hughes *et al.*
Serial No. : 10/799,072
Filed : March 12, 2004
For : Genes and Proteins, and Their Use

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.97 and §1.98, the applicants would like to bring to the attention of the Examiner, the references cited in the following patent application:

U.S. Serial No. 09/868,352, filed June 15, 2001.


The subject application, Serial No. 10/799,072, claims the benefit under 35 USC §120 of the filing date of patent application Serial No. 09/868,352. The applicants respectfully request that the copies of references supplied in the Information Disclosure Statement of the 09/868,352 application, as well as references cited during the prosecution thereof, be made of record in the 10/799,072 application.

As copies of the references filed in the 09/868,352 application, and cited on the attached form PTO/SB/08, can be found in the 09/868,352 case file, copies of those references are not provided herewith.

It is respectfully requested that the references cited in the 09/868,352 application be considered in the examination of the subject application and that their consideration be made of record.

The applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,



Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41st Street, Suite A-1
Gainesville, FL 32606-6669

GPL/mv

Attachment: Form PTO/SB/08 (2 pages)



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/799,072	
			Filing Date	March 12, 2004	
			First Named Inventor	Martin John Glenton Hughes	
			Art Unit	1653	
Sheet	1	of	2	Examiner Name	
				Attorney Docket Number	GJE-70D1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code ² (if known)			
	U1	US-2003/0104000 A1	06-05-2003	Hughes et al.	All
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 00/06736	02-10-2000	Microbial Technics Limited	All	
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/799,072	
			Filing Date	March 12, 2004	
			First Named Inventor	Martin John Glenton Hughes	
			Group Art Unit	1653	
			Examiner Name		
Sheet	2	of	2	Attorney Docket Number	GJE-70D1

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	R1	BURGESS, W.H. <i>et al.</i> "Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor-1 from its receptor-binding activities by site-directed mutagenesis of a single lysine residue" <i>J. Cell Biology</i> , 1990, 111:2129-2138.		
	R2	COFFEY, T. <i>et al.</i> "Recombinational exchanges at the capsular polysaccharide biosynthesis locus..." <i>Molecular Microbiology</i> , June 1998, 27:73-83; EMBL Database Accession no. 054547, Sequence ID 054547. Sequence only.		
	R3	ELLIS, R.W. "New technologies for making vaccines" Chapter 29 of "Vaccines" Plotkin, S. and Mortimer, E. Eds., published by W.B. Saunders company, Philadelphia, 1988.		
	R4	GIFFARD, P.M. <i>et al.</i> Sequence ID CLPP_STRSL, June 1, 1994, EMBL Database Accession no P36398.		
	R5	GIFFARD, P.M. <i>et al.</i> "The <i>ftf</i> gene encoding the cell-bound fructosyltransferase of <i>Streptococcus salivarius</i> ATCC 25975 is preceded by an insertion sequence and followed by <i>FUR1</i> and <i>clpP</i> homologues" <i>Journal of General Microbiology</i> , 1993, 139:913-920.		
	R6	JOBLING, M.G. and HOLMES, R.K. "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis" <i>Molecular Microbiol.</i> , 1991, 5(7):1755-1767.		
	R7	LAZAR, E. <i>et al.</i> "Transforming growth factor α : Mutation of aspartic acid 47 and leucine 48 results in different biological activities" <i>Mole. and Cell. Biol.</i> , 1988, 8(3):1247-1252.		
	R8	LARSSON, C. <i>et al.</i> "Experimental Vaccination Against Group B Streptococcus, an Encapsulated Bacterium, with Highly Purified Preparations of Cell Surface Proteins Rib and α " <i>Infection and Immunity</i> , 1996, 64(9):3518-3523.		
	R9	MAURIZI, M.R. <i>et al.</i> "Sequence and Structure of Clp P, the Proteolytic Component of the ATP-dependent Clp Protease of <i>Escherichia coli</i> " <i>J. Biol. Chem.</i> , July 1990, 265(21):12536-12545.		
	R10	RUDINGER, J. "Characteristics of the amino acids as components of a peptide hormone sequence" in "Peptide Hormones" Parsons, J.A., Ed., University Park Press, June 1976, page 6.		
	R11	TSUKIOKA, Y. <i>et al.</i> "Biological Function of the dTDP-Rhamnose Synthesis Pathway in <i>Streptococcus mutans</i> " <i>Journal of Bacteriology</i> , February 1997, 179(4):1126-1134.		
	R12	WASTFELT, M. <i>et al.</i> "Identification of a Family of Streptococcal Surface Proteins with Extremely Repetitive Structure" <i>J. Biol. Chem.</i> , August 1996, 271(31):18892-18897.		
	R13	YUICHI, T. <i>et al.</i> , Sequence ID P95779, May 1, 1997, EMBL Database Accession no P95779.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.